Arvenacogene Sanparvovec

N/A

Report date: 2025/08/22 17:51:56

Base Information

Drug NameArvenacogene Sanparvovec
Drug Alias NameANB-2ANB-002
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV5 vector
Mechanisms of ActionFactor IX gene transference
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryThailandRussian FederationBelarus
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesBIOCAD JSC
Inactive CompaniesN/A
Active IndicationsHemophilia B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A